The National Agency for Health Security (ANSES) published Tuesday, July 20 a report in which it requests the placement, on the list of carcinogenic substances, eighteen products used in the treatment of cancer. The risk is greater for caregivers.
Eighteen cytostatic products deemed carcinogenic
The National Health Security Agency (ANSES) ruled on Tuesday July 20, 2021 that eighteen cytostatic products, that is to say eighteen products used to treat cancer, were themselves carcinogenic. ANSES therefore asks in its report that these products are placed on the list of carcinogenic substances. While the products have a positive effect on patients, particularly in the context of chemotherapy, they are dangerous for caregivers.
The inclusion of these products on the list of carcinogenic substances, according to ANSES, is intended to “ promote the dissemination of information and training for the professionals concerned by making them aware of the circumstances of exposure to these drugs “. According to the Agency’s findings, 92,000 people are exposed to these treatments, which are used in hospital care but also at home.
” Protective measures »For caregivers
Thus, if many caregivers are exposed to its substances, many don’t know they are, as confirmed to France Info, Henri Bastos, director of occupational health at ANSES. He explains : ” many employers, employees or professionals do not necessarily know that they can be exposed during their professional activity “, Although these substances are present” throughout the exhibition chain, which goes from manufacturing to waste management “.
If the European regulation does not consider these eighteen products as part of its list of ” mutagenic and reprotoxic carcinogenic chemicals (CMR), because of their drug status, the National Agency for Health Security wishes to put in place protective measures for caregivers.